Valchlor is owned by Helsinn.
Valchlor contains Mechlorethamine Hydrochloride.
Valchlor has a total of 6 drug patents out of which 0 drug patents have expired.
Valchlor was authorised for market use on 23 August, 2013.
Valchlor is available in gel;topical dosage forms.
Valchlor can be used as alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy.
The generics of Valchlor are possible to be released after 08 July, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8501819 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US9382191 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US8450375 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US8501818 | HELSINN | Stabilized compositions of alkylating agents and methods of using same |
Mar, 2026
(3 years from now) | |
US7838564 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(3 years from now) | |
US7872050 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Jul, 2029
(6 years from now) |
Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL;TOPICAL
20
United States
3
Poland
3
Lithuania
3
Spain
3
Slovenia
3
Hungary
3
Portugal
3
China
3
New Zealand
3
Denmark
3
European Union
2
Japan
2
Croatia
1
Hong Kong
1
Korea, Republic of
1
Australia
1
Luxembourg
1
Cyprus
1
Turkey
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic